StockNews.AI
OTLK
StockNews.AI
26 days

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

1. OTLK to present at OIS Retina Innovation Summit on July 29. 2. CEO Bob Jahr will showcase advancements in retinal disease therapies. 3. LYTENAVA™ is launched in Germany and the UK; U.S. approval pending. 4. First ophthalmic bevacizumab formulation approved in Europe for wet AMD. 5. Innovative therapies in ocular diseases will be highlighted at the summit.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive presentation and FDA resubmission could attract investor interest, similar to previous biotech rallies after key events.

How important is it?

The summit will likely increase visibility and interest in OTLK's projects, particularly in light of their unique market position.

Why Short Term?

Immediate investor attention expected around the event date and potential FDA updates.

Related Companies

AVDXREGNBMY
July 24, 2025 09:00 ET  | Source: Outlook Therapeutics, Inc. ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the 8th Annual OIS Retina Innovation Summit being held on July 29, 2025 in Long Beach CA. Details for the presentations are as follows:Session: Innovation Showcase Presenter: Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Tuesday, July 29, 2025, 8:35 – 9:35 AM PT For more information and to register for this event, please visit OIS Retina @ ASRS.About the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase Launched in 2009, the Ophthalmology Innovation Summit serves to showcase novel therapies in development for unmet needs in ophthalmic disease and vision disorders, bringing together entrepreneurs, ophthalmic start-up companies, clinical thought leaders, industry executives and investment professionals to facilitate an exchange of information and connections to drive innovation in the retina, anterior segment, and optometry. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Investor Inquiries:Jenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775OTLK@jtcir.com

Related News